{
	"assertions": [
		{
			"id": 3, 
			"context": null, 
			"description": "The U.S. Food and Drug Administration (FDA) granted approval for dasatinib for adults with Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.", 
			"disease": {
				"name": "Acute Lymphoid Leukemia", 
				"oncotree_code": "ALL", 
				"oncotree_term": "Acute Lymphoid Leukemia"
			}, 
			"therapy_name": "Dasatinib", 
			"therapy_type": "Targeted therapy", 
			"clinical_significance": "sensitivity", 
			"predictive_implication": "FDA-Approved", 
			"feature_ids": [3], 
			"favorable_prognosis": null, 
			"created_on": "01/16/21", 
			"last_updated": "2020-11-12", 
			"submitted_by": "breardon@broadinstitute.org", 
			"validated": true, 
			"source_ids": [2], 
			"variant": {
				"id": 3,
				"feature_type": "rearrangement", 
				"rearrangement_type": "Fusion", 
				"gene1": "BCR", 
				"gene2": "ABL1", 
				"locus": null, 
				"feature": "BCR--ABL1 Fusion"
			}
		}
	], 
	"sources": [
		{
			"id": 2, 
			"type": "FDA", 
			"assertion_id": [2, 3], 
			"doi": null, 
			"nct": null, 
			"pmid": "None", 
			"url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf", 
			"citation": "Bristol-Myers Squibb Company. Sprycel (dasatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf. Revised December 2018. Accessed November 12, 2020."
		},
		{
			"id": 22, 
			"type": "Journal", 
			"assertion_id": [30, 288], 
			"doi": "10.1371/journal.pgen.1004135", 
			"nct": null, 
			"pmid": "24550739", 
			"url": "https://doi.org/10.1371/journal.pgen.1004135", 
			"citation": "Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135."
		}
	], 
	"variants": [
		{
			"id": 3,
			"feature_type": "rearrangement", 
			"rearrangement_type": "Fusion", 
			"gene1": "BCR", 
			"gene2": "ABL1", 
			"locus": null, 
			"feature": "BCR--ABL1 Fusion"
		},
		{
			"id": 296,
			"feature_type": "somatic_variant",  
			"gene": "EZH2", 
			"chromosome": "7", 
			"start_position": "148508728.0", 
			"end_position": "148508728.0", 
			"reference_allele": "A", 
			"alternate_allele": "T", 
			"cdna_change": "c.1936T>A", 
			"protein_change": "p.Y646N", 
			"variant_annotation": "Missense", 
			"exon": "16.0", 
			"rsid": null, 
			"feature": "EZH2 p.Y646N (Missense)"
		}
	]
}